Fact CheckerSign in

NCT06814548Not yet recruiting

Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study

Source: ClinicalTrials.gov · Last updated 7 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

This is a single-center, retrospective, observational, real-world study. We collected general and clinical data of patients with advanced gastric cancer who were admitted to the First Affiliated Hospital of Zhengzhou University from January 2018 to July 2024.

Status (registry)
Not yet recruiting
Study type
Observational
Enrollment
200 (estimated)
First submitted
3 Feb 2025
Start date
10 Feb 2025
Primary completion date
31 May 2025
Lead sponsor
Yongxu Jia
NCT number
NCT06814548

What you commit to

  • Study type: Observational
  • Planned participants: 200
  • From 10 Feb 2025 to the primary completion date, 31 May 2025
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • combined radiotherapy regimens in the second-line treatment.

Other illness

  • patients had other malignancies within the past 5 years;

Other

  • lack of survival and clinical efficacy data;

Who the study is looking for

  • Histologically confirmed metastatic or advanced GC/GEJC;
  • Received at least 2 cycles of anti-PD-1 or PD-L1 based therapy in the first-line setting;
  • Receiving at least 2 cycles of ICI-based second-line therapy;
  • ECOG PS 0 or 1;
  • Radiographic response was also assessed during treatment and survival.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.